Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57.
Наслов
Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57.
Опис
J. Rožić, Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57., This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011., 2011.
Идентификатор
/unibl/sci/idNaucniRad:8551
Тип
Пронађите сличне уносеArticle
Датум
Библиографски цитат
J. Rožić, Z. Gojković, S. Jungić, I. Rakita, Ž. Vranješ, R. Rašeta, G. Marić, M. Vještica, S. Mijatović, P. Dašić, M. Vižin, Sorafenib as first line treatment for advanced liver cancer-are expiries. Ann Oncol (2011) 23 (suppl 4): iv 57., This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011., 2011
Презентовано
This article appears in ESMO 13th World Congres of Gastrointestinal Cancer, 22-25 june 2011.
Листа аутора
Position: 1771 (40 views)